Structure-activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2α-mediated arachidonic acid release in intact platelets: Variation of the keto moiety

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 20, Issue 5, 2005, Pages 429-437

  Ghasemi, Afshin ^a   Schulze Elfringhoff, Alwine ^a   Lehr, Matthias ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

3 dodecanoylindole 2 carboxylic acid; Cytosolic phospholipase A2; Inhibition; Inhibitors; Structure activity relationships

Indexed keywords

1 [2 (4 CARBOXY 2 FLUOROPHENOXY)ETHYL] 3 DODECANOYLAMINOINDOLE 2 CARBOXYLIC ACID; 1 [2 (4 CARBOXY 2 FLUOROPHENOXY)ETHYL] 3 DODECYLSULFINYLINDOLE 2 CARBOXYLIC ACID; 1 [2 (4 CARBOXYPHENOXY)ETHYL] 3 DODECANOYLAMINOINDOLE 2 CARBOXYLIC ACID; 1 [2 (4 CARBOXYPHENOXY)ETHYL] 3 DODECANOYLINDOLE 2 CARBOXYLIC ACID; 1 METHYLDODECANOYLINDOLE 2 CARBOXYLIC ACID; 3 (DODECANOYLAMINOMETHYL) 1 METHYLINDOLE 2 CARBOXYLIC ACID; 3 DODECANOYLAMINO 1 METHYLINDOLE 2 CARBOXYLIC ACID; 3 DODECYLSULFAMOYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; 3 DODECYLSULFINAMOYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; 3 DODECYLSULFINYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; 3 DODECYLSULFONYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; ARACHIDONIC ACID; CARBOXYLIC ACID DERIVATIVE; ETHYL 3 DODECANOYLAMINO 1 METHYLINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECANOYLAMINOINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFAMOYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFANYLINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFINAMOYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFINYL 1 [2 (4 ETHOXYCARBONYL 2 FLUOROPHENOXY)ETHYL]INDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFINYL 1 [2 (4 ETHOXYCARBONYLPHENOXY)ETHYL]INDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFINYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; ETHYL 3 DODECYLSULFONYL 1 METHYLINDOLE 2 CARBOXYLIC ACID; INDOLE DERIVATIVE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME ISOLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ARACHIDONIC ACID; BINDING SITES; BLOOD PLATELETS; CALCIMYCIN; ENZYME INHIBITORS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PHOSPHOLIPASES A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28244453161     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360500228338     Document Type: Article

References (28)

1. Serhan CN, Haeggström JZ, Leslie CC. FASEB J 1996; 10:1147-1158.
2. Huang YH,Schafer-Elinder L, Wu R, Claesson HE, Frostegard. J Clin Exp Immunol 1999;116:326-331.
3. Ryborg AK, Deleuran B, Sogaard HR, Kragballe K. Acta Derm. Venereol 2000;80:242-246.
4. Connolly S, Robinson DH. Expert Opin Ther Pat 1993; 3:1141-1155.
5. Connolly S, Robinson DH. Expert Opin Ther Pat 1995; 5:673-683.
6. Tibes U, Friebe WG. Expert Opin Investig Drugs 1997;6:279-298.
7. Mayer RJ, Marshall LA. Emerging Drugs 1998;3:333-344.
8. Lehr M. Expert Opin Ther Pat 2001;11:1123-1136.
9. Six LA, Dennis EA. Biochim Biophys Acta 2000;1488:1-19.
10. Lin LL, Lin AY, Knopf JL. Proc Nat Acad Sci USA 1992;89:6147-6151.
11. Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Koma-gata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J, Shimizu T. Nature 1997;390:618-622.
12. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Nature 1997;390:622-625.
13. Gijon MA, Spencer DM, Siddiqi AR, Bonventre JV, Leslie CC. J Biol Chem 2000;275:20146-20156.
14. Lehr M. J Med Chem 1997;40:2694-2705.
15. Lehr M, Schulze Elfringhoff A. Arch Pharm Pharm Med Chem 2000;333:312-314.
16. Lehr M, Klimt M, Schulze Elfringhoff A. Bioorg Med Chem Lett 2001;11:2569-2572.
17. Dannhardt G, Lehr M. J Pharm Pharmacol 1992;44:419.
18. Dannhardt G, Steindl L, Lehr M. Chem Abstr 1991;114:163999, EP 397175 1990.
19. Lehr, M, PhD Thesis University of Regensburg 1989.
20. Laufer SA, Augustin J, Dannhardt G, Kiefer W. J Med Chem 1994;37:1894-1897.
21. Laufer S. Inflammopharmacology 2001;9:101-112.
22. Schmitt M, Lehr M. J Pharm Biomed Anal 2004;35:135-142.
23. Connolly S, Bennion C, Botterell S, Croshaw PJ, Hallam C, Hardy K, Hartopp P, Jackson CG, King SJ, Lawrence L, Mete A, Murray D, Robinson DH, Smith GM, Stein L, Walters I, Wells E, Withnall WJ. J Med Chem 2002;45:1348-1362.
24. Ghomashchi F, Loo R, Balsinde J, Bartoli F, Apitz-Castro R, Clark JD, Dennis EA, Gelb MH. Biochim Biophys Acta 1999;1420:45-56.
25. Unangst PC, Connor DT, Stabler SR. J Heterocycl Chem 1987;24:817-820.
26. Tamura Y, Kwon S, Chun MW, Ikeda M. J Heterocycl Chem 1978;15:425-427.
27. Lehr M. Arch Pharm Pharm Med Chem 1996;329:386-392.
28. Griessbach K, Klimt M, Schulze Elfringhoff A, Lehr M. Arch Pharm Pharm Med Chem 2002;335:547-555.